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ABSTRACT
Introduction: Data from different healthcare
systems on relative cost-effectiveness of
asthma step-up therapy strategies are required
to inform decision-makers and clinicians. Our
objective was to compare cost-effectiveness
from the United Kingdom National Health
Service perspective of three step-up strategies
for patients with asthma uncontrolled by
inhaled corticosteroid (ICS) monotherapy.
Methods: This was a historical matched cohort
cost-effectiveness analysis of anonymized
medical records for patients with asthma of
age 12–80 years. We conducted two-way
comparisons of step-up therapy using
increased dose (C50%) of extrafine-particle ICS
or add-on long-acting b2-agonist (LABA) via
fixed-dose combination (FDC) ICS/LABA
inhaler or via separate inhaler. The
incremental cost-effectiveness ratio (ICER) was
calculated using asthma-related direct costs
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during one outcome year and a composite
measure of risk-domain asthma control (no
asthma-related hospital attendance, acute oral
corticosteroids, or consultation for lower
respiratory tract infection).
Results: Patients prescribed ICS dose step-up
(n = 3036) had significantly lower
baseline-adjusted, mean asthma-related
healthcare costs during the outcome year than
those prescribed FDC ICS/LABA (n = 3036;
mean difference, £124/year). ICS dose step-up
had 56% probability of being less costly and
marginally less effective (a trade-off), with ICER
of £51,449 per additional patient controlled
with FDC; and ICS dose step-up had 44%
probability of being the preferred treatment
strategy (less costly and more effective). In a
second comparison, ICS step-up (n = 3232) had
100% probability of being cheaper and more
effective than adding LABA to ICS via separate
inhalers (n = 6464).
Conclusion: For asthma step-up therapy,
increasing ICS dose using extrafine-particle ICS
is significantly less costly from the payer
perspective and marginally (non-significantly)
less effective than FDC ICS/LABA therapy
containing standard fine-particle ICS. These
findings apply primarily to the UK healthcare
system but warrant consideration when
developing guidelines in settings with strong
economic constraints.
Trial Registration: ClinicalTrials.gov identifier:
NCT01697722.
Funding: Teva Pharmaceuticals Limited, Petach
Tikva, Israel.
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INTRODUCTION
An estimated 334 million people worldwide
have asthma, including 5.4 million people in
the United Kingdom (UK) on current asthma
therapy [1, 2]. Asthma is an important cause of
healthcare resource utilization and
health-related quality of life impairment [3].
The treatment of asthma is expensive, costing
the UK National Health Service (NHS) an
estimated £1 billion per year in direct costs,
mostly attributable to the cost of prescription
medications and hospital admissions [2, 4].
Healthcare resource use and the direct costs of
asthma are highest for patients with suboptimal
asthma control [5–7]. Considering these costs, it
is of utmost importance to generate real-life
cost-effectiveness data to help decision-makers
and clinicians in their decisions regarding the
choice between available treatment options.
The goal of asthma therapy is to achieve the
two facets of asthma control, namely, current
symptomatic control and minimized risk of
future acute exacerbations, which can be life
threatening [3]. Asthma therapy is prescribed
using a stepwise approach, beginning with
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short-acting bronchodilator (reliever
medication, such as short-acting b2-agonist
[SABA]) at step 1 and progressing, as needed,
to controller or maintenance therapy at step 2
with an anti-inflammatory medication, such as
an inhaled corticosteroid (ICS). For patients
receiving ICS monotherapy whose asthma
remains uncontrolled, asthma management
guidelines then recommend at step 3 the
addition of a long-acting bronchodilator (e.g.,
long-acting b2-agonist [LABA]), with secondary
(less-preferred) options of increasing the ICS
dose or adding a leukotriene receptor
antagonist (LTRA) [3, 8].
These recommendations are based on the
results of randomized controlled trials (RCTs)
[3, 8]; however, RCT results have limited
generalizability to actual clinical practice. By
one estimate up to 95% of patients with asthma
would not be eligible for RCTs because of
restrictive RCT eligibility criteria, such as the
exclusion of smokers or obese patients [9].
Moreover, adherence to therapy and inhaler
device technique are better in RCTs than among
patients in clinical practice [10, 11]. Relevantly
for the step-up comparisons between increasing
ICS dose and add-on LABA, most RCTs require
enrolled patients to demonstrate substantial
reversibility of airflow obstruction to a SABA,
thereby selecting for bronchodilator
responsiveness and excluding the estimated
70% of patients with asthma who fail to
demonstrate sufficient bronchodilator
reversibility at any given point in time [9].
Cost-effectiveness analyses of asthma
therapies are usually based on economic
models drawing on data from RCTs of
12–16 weeks’ duration [12–15]. However,
long-term clinical practice data may be more
directly relevant to inform economic decisions
regarding treatment choices for asthma, and
effectiveness parameters such as annual
exacerbation rates may be more appropriate for
making treatment decisions [16, 17]. In addition,
most economic models relied on RCTs in which
standard fine-particle ICS were administered,
namely, ICS with particles of median mass
aerodynamic diameter (MMAD) of[2–5 lm.
Instead, the newer extrafine-particle ICS
(MMAD,*1 lm) may better treat the small
airways, where inflammation is often present in
asthma, and thus may be more effective than
fine-particle ICS, at least for patients with small
airway involvement [18, 19].
In a prior historical matched cohort study
comparing step-up alternatives for patients with
asthma treated in community settings [20], we
found that increasing the ICS dose was as
effective in controlling exacerbations over the
subsequent year as adding a LABA by fixed-dose
combination (FDC) ICS/LABA inhaler. The
objective of the present historical matched
cohort cost-effectiveness analysis was to
compare direct asthma-related healthcare costs
and cost-effectiveness from the UK NHS
perspective of three common step-up options
for asthma: increased dose of extrafine-particle
ICS, add-on LABA by FDC ICS/LABA inhaler,
and add-on LABA by separate inhaler. Our
hypothesis was that increasing the dose of an
extrafine-particle ICS would be a cost-effective
alternative to therapy with ICS plus LABA in
combination or separate inhalers for adults with
evidence of persistent asthma. Additionally, we
hypothesized that FDC ICS/LABA inhalers
would be more cost-effective than separate
ICS/LABA inhalers.
METHODS
Data Sources and Patients
The anonymized patient data for this matched
cohort study were drawn from two UK primary
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care electronic datasets used extensively for
pharmacoepidemiologic research and described
in detail in prior publications: the General
Practice Research Database (GPRD), now part of
the Clinical Practice Research Datalink, and the
Optimum Patient Care Research Database
(OPCRD) [21–24]. Approval was given for use of
the GPRD data by the GPRD Independent
Scientific Advisory Committee. The OPCRD has
been approved by Trent Multi Centre Research
Ethics Committee for clinical research use, and
the study protocol was approved by ADEPT
(Anonymised Data Ethics Protocols and
Transparency Committee), OPC’s independent
scientific advisory committee. Informed patient
consent was neither required nor possible to
obtain for this non-interventional study using
anonymized data. The study was conducted
according to standards recommended for
observational research (further details in the
supplementary material) [25].
The study period ran from January 1997
through January 2011. We included patients
with asthma and no other chronic respiratory
disease who were 12–80 years old. We excluded
active smokers who were 61–80 years old because
undiagnosed or comorbid chronic obstructive
pulmonary disease is more likely in this older age
group than in younger patients [3, 8]. Additional
inclusion criteria were ICS monotherapy for
asthma during one baseline year; a step up in
asthma therapy as one of the three options
described below; and 2 years of continuous
records in the GPRD or the OPCRD, including
one baseline year before and one outcome year
after the step-up date (defined as the index date).
The three step-up options were as follows:
(1) Extrafine ICS step-up: an increase in ICS
dose of C50% as an extrafine-particle ICS
(beclomethasone dipropionate
hydrofluoroalkane [HFA]; Qvar, Teva
Pharmaceutical Industries Ltd., Petach
Tikva, Israel), by pressurized metered-dose
inhaler (pMDI) or breath-actuated pMDI
(BAI)
(2) FDC ICS/LABA: addition of LABA (with no
change in ICS dose) using a fixed-dose ICS/
LABA combination of either fluticasone
propionate/salmeterol xinafoate
(Seretide, GlaxoSmithKline, Middlesex,
UK), or budesonide/formoterol fumarate
dihydrate (Symbicort, AstraZeneca,
London, UK); or
(3) Separate ICS ? LABA: addition of LABA by
separate pMDI or BAI, with no change in
ICS drug, dose, or inhaler.
Resource Use and Costs
Information on asthma-related resource use was
extracted from the databases. We calculated
total asthma-related direct costs in 2011 sterling
(£) from the UK NHS perspective using unit
costs obtained from UK national data sources
[26–28], summarized in supplementary
Table S1, with further details in the
supplemental Methods section in the
supplementary material.
Effectiveness Measure
We used a composite database measure for
risk-domain asthma control as the
effectiveness measure, as reported in previous
publications [20, 29–31], defining asthma
control as including all of the following: (1)
no asthma-related hospital attendance or
admission, emergency department (ED)
attendance, out-of-hours attendance, or
outpatient hospital attendance; and (2) no
prescription for an acute course of oral
corticosteroids [32]; and (3) no primary care
consultation for lower respiratory tract
infection [33, 34].
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Statistical Analyses
We conducted matched cohort analyses, using
two-way matching for the three cohorts, to
compare outcomes for age- and sex-matched
patients with similar asthma severity and
baseline asthma control. Patients were
matched sequentially on sex, age, the last ICS
daily dose prescribed before the index date,
asthma control status, mean daily dose of SABA,
and the number of primary care consultations
for asthma with no oral corticosteroid
prescription (details in the supplementary
material). Effectiveness and asthma-related
costs were compared by two-way comparisons
between (1) the ICS step-up cohort versus the
FDC ICS/LABA cohort (comparison 1); (2) the
ICS step-up cohort versus the separate
ICS ? LABA cohort (comparison 2); and (3) the
separate ICS ? LABA cohort versus the FDC ICS/
LABA cohort (comparison 3).
The costs of treatments were compared via
the differences in mean asthma-related
healthcare costs per patient per year during
the outcome period, both unadjusted and
adjusted for potential confounders (Table S2 in
the supplementary material). Two-way
comparisons of summary costs between
matched cohorts were carried out using
conditional logistic regression. Generalized
linear models with a log link and gamma
distribution were used to estimate adjusted
mean asthma-related healthcare costs per year
during the outcome period. Differences in
adjusted mean costs are reported with 95%
confidence intervals (CIs) found by
bootstrapping methods, using 1000 random
samples taken, with replacement, from the
dataset [35].
The effectiveness of treatments for matched
cohorts was compared via the difference in the
proportion of patients with asthma control
during the outcome year, both unadjusted and
adjusted for potential confounders. Adjusted
proportions were estimated using generalized
linear models with a logit link and binomial
distribution. Proportions and differences in
proportions of patients with asthma control
were reported with 95% CIs found by
bootstrapping methods, using the 1000
random samples taken, with replacement,
from the dataset.
The two-way differences in total
asthma-related costs and proportions of
patients with asthma control for the 1000
random samples were displayed graphically on
cost-effectiveness planes. When the point
estimates for differences in costs and
effectiveness indicated a trade-off between
treatments (Fig. 1, quadrants I and III), we
calculated an incremental cost-effectiveness
ratio (ICER) as the ratio of the difference in
total asthma-related healthcare costs per patient
per year (namely, the incremental cost) to the
difference in proportions of patients with
asthma control (namely, the incremental gain
in effectiveness). When all the replicated data
were in one quadrant of the cost-effectiveness
plane, the ICER was reported with a 95% CI
found by bootstrapping methods. When
replicated data covered more than one
quadrant, we produced a cost-effectiveness
acceptability curve (CEAC) in conjunction
with the ICER [36–38].
RESULTS
Patients
We identified 5492, 9207, and 20,657 eligible
patients who were prescribed extrafine-particle
ICS dose step-up, add-on LABA by FDC ICS/
LABA inhaler, and add-on LABA to ICS by
separate LABA inhaler, respectively. The
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Fig. 1 Cost-effectiveness planes showing the spread of the
estimated differences in cost and effectiveness, based on
1000 replicated samples, between a the ICS step-up cohort
and the FDC ICS/LABA cohort and b the ICS step-up
cohort and the separate ICS ? LABA cohort. Depending
where the data points lie, the four quadrants of the
cost-effectiveness plane would depict the results of a step-up
in asthma therapy by increased dose of extraﬁne-particle
ICS, relative to add-on LABA with ICS in combination
(a) or separate (b) inhalers, as follows: Quadrant I: ICS
step-up more costly and more effective (a trade-off);
Quadrant II: ICS step-up more costly and less effective
(thus, FDC ICS/LABA or separate ICS ? LABA domi-
nant); Quadrant III: ICS step-up less costly and less
effective (a trade-off); and Quadrant IV: ICS step-up less
costly and more effective (ICS step-up dominant). FDC
ﬁxed-dose combination, ICS inhaled corticosteroid, LABA
long-acting beta2-agonist
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matching for the ICS step-up cohort versus the
separate ICS ? LABA cohort and for the FDC
ICS/LABA cohort versus the separate
ICS ? LABA cohort was in 1:2 ratios because of
a baseline imbalance in numbers of unmatched
patients. Baseline characteristics of matched
patients in comparisons 1 and 2 are in
Table S3 in the supplementary material.
Approximately 22% of patients in comparisons
1 and 2 were smokers, and approximately 18%
were ex-smokers (Table S3).
Full results for comparison 3 (FDC ICS/LABA
versus separate ICS ? LABA) are reported in
Tables S4–S6 in the supplementary material.
In all matched cohorts uncontrolled asthma
was associated with increased costs (Table S7).
Comparison 1: Asthma Step-Up Therapy
Using an Increased Dose
of Extrafine-Particle ICS Versus Add-On
LABA by FDC ICS/LABA Inhaler
After matching, there were 3036 patients in the
ICS step-up and the FDC ICS/LABA cohorts.
Patients’ mean (standard deviation) age was 43
(16) years, 60% being women (Table S3 in the
supplementary material).
The percentage of patients meeting the
risk-domain asthma control measure increased
from 65% at baseline to 75% in both cohorts
during the outcome year. The complete
effectiveness results for comparison 1 have
been previously published [20].
During the outcome year, asthma-related
resource use was similar in the two cohorts
with the exception of expected differences
related to study design, such as use of ICS and
FDC ICS/LABA inhalers and a greater number of
SABA inhalers used by the ICS step-up cohort
(Table 1). The mean baseline-adjusted,
asthma-related healthcare costs for patients in
the ICS step-up cohort were significantly lower
than those for patients in the FDC ICS/LABA
cohort (mean, £203 vs. £327; Table 2). When
adjusted mean costs were combined with the
adjusted effectiveness results—using asthma
control as the effectiveness measure—there
was a 56% probability that stepping up to a
higher dose of extrafine-particle ICS would be
less costly but less effective (a trade-off) and a
44% probability that ICS step-up would be the
preferred treatment strategy (less costly and
more effective). The uncertainty around the
point estimates is illustrated in the
cost-effectiveness plane (Fig. 1a). The point
estimate for the ICER was £51,449. The CEAC
showed that for no additional cost (willingness
to pay = £0) an increased dose of the
extrafine-particle ICS was the cost-effective
option, since a zero value for the willingness
to pay implies that only the cost is important in
the cost-effectiveness calculation (Fig. 2).
Comparison 2: Asthma Step-Up Therapy
Using an Increased Dose
of Extrafine-Particle ICS Versus Add-On
LABA by Separate Inhaler
After matching, there were 3232 patients in the
ICS step-up cohort and 6464 patients in the
separate ICS ? LABA cohort. Baseline patient
characteristics and asthma-related resource use
were similar to those of comparison 1 (Table S3
in the supplementary material).
The percentage of patients meeting the
risk-domain asthma control measure increased
from 65% at baseline to 75% in the ICS step-up
cohort and to 71% in the separate ICS ? LABA
cohort at outcome.
During the outcome year, most categories of
asthma-related resource use and costs were
significantly lower for the ICS step-up cohort
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Table 1 Mean asthma-related drug prescriptions and unadjusted costs during the outcome year for patients receiving a
step-up in ICS dose versus add-on LABA by FDC ICS/LABA inhaler (comparison 1)
Asthma-related resourceb Mean (SD) resource use Mean (SD) resource cost, £
ICS dose
step-up
(N5 3036)
FDC ICS/
LABA
(N5 3036)
P valuea ICS dose
step-up
(N5 3036)
FDC ICS/
LABA
(N5 3036)
P valuea
ICS inhalers 5.7 (4.1) 0.8 (2.3) \0.001 92 (68) 8 (24) \0.001
FDC ICS-LABA inhalers 0.9 (3.2) 8.8 (7.3) \0.001 34 (135) 245 (198) \0.001
Long-acting b2-agonist inhalers 0.8 (22.4) 0.2 (4.6) \0.001 11 (51) 3 (29) \0.001
Short-acting b2-agonist inhalers 7.1 (7.7) 5.4 (7.1) \0.001 27 (58) 22 (55) \0.001
Leukotriene receptor antagonist
prescriptions
0.2 (1.1) 0.2 (1.2) 0.11 6 (41) 7 (40) 0.28
Antibiotic prescriptionsc 1.0 (1.6) 1.0 (1.5) 0.39 3 (11) 4 (15) 0.30
Oral corticosteroid prescriptions 0.3 (1.0) 0.3 (0.9) 0.067 1 (7) 1 (5) 0.67
Total mean medication costs – – – 174 (182) 290 (220) \0.001
Total mean medication costs,
excluding ICS
– – – 49 (92) 37 (77) \0.001
Primary care asthma
consultations
0.9 (1.3) 0.9 (1.3) 0.12 32 (47) 34 (46) 0.12
Total asthma-related
hospitalizations
0.0 (0.3) 0.1 (0.3) 0.21 9 (67) 10 (68) 0.34
Asthma-related inpatient 0.0 (0.1) 0.0 (0.1) 0.72 3 (54) 4 (54) 0.72
Asthma-related outpatient 0.0 (0.2) 0.0 (0.3) 0.25 5 (34) 6 (36) 0.25
Asthma-related emergency
department visit
0.0 (0.1) 0.0 (0.1) 0.64 0.7 (11) 0.9 (12) 0.64
Total asthma-related primary and
secondary care, including ICS
costs
– – – 215 (226) 334 (254) \0.001
Total asthma-related primary and
secondary care, excluding ICS
costs
– – – 90 (139) 81 (123) \0.001
Mean values are reported, despite substantially skewed distributions, because mean values can be multiplied by a target
population to estimate total costs and thus are of most interest for policy makers and providers
FDC Fixed-dose combination, ICS Inhaled corticosteroid, LABA Long-acting b2-agonist, SD Standard deviation
a Conditional logistic regression
b Asthma-related includes all database events coded for asthma and lower respiratory tract infection
c Antibiotics prescribed with accompanying lower respiratory tract infection Read code
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(Table 3), and the mean baseline-adjusted,
asthma-related healthcare costs for patients in
the ICS step-up cohort were significantly lower
compared with those for patients remaining on
the same ICS dose but adding a separate LABA
(£204 vs. £337; Table 2). When costs were
combined with the adjusted effectiveness
results, there was a 100% probability that
stepping up to a higher dose of
extrafine-particle ICS would be less costly and
more effective than adding a LABA by separate
inhaler (Fig. 1b).
DISCUSSION
In this matched cohort cost-effectiveness study,
UK patients stepping up to a higher dose of
extrafine-particle ICS had significantly lower
baseline-adjusted mean asthma-related
healthcare costs compared with patients
stepping up to an FDC ICS/LABA inhaler
(mean difference of £124 per annum) during
one outcome year. When these costs were
combined with the adjusted effectiveness
results, there was a 56% probability that
Table 2 Incremental cost-effectiveness analysis: ICS step-up versus FDC ICS/LABA inhaler (comparison 1) and ICS
step-up versus ICS ? LABA in separate inhalers (comparison 2)
Comparison 1 Comparison 2
ICS dose
step-up
(N5 3036)
FDC ICS/
LABA
(N5 3036)
ICS dose
step-up
(N5 3232)
Separate
ICS 1 LABA
(N5 6464)
Risk-domain asthma control, adjusted
OR (95% CI)
0.99 (0.88–1.12)a 1.00 1.25 (1.13–1.38)d 1.00
Risk-domain asthma control, adjusted
proportion (95% CI)b
0.44 (0.37–0.50)a 0.44
(0.37–0.51)a
0.61 (0.59–0.63)d 0.56
(0.53–0.58)d
Difference relative to add-on LABA
(95% CI)b
0.002 (-0.033 to
0.026)
0.06 (0.03–0.08)
Adjusted mean asthma-related
healthcare costs per patient per year
(95% CI)b,c
£203 (£197–£210) £327
(£319–£336)
£204 (£197–£210) £337
(£332–£344)
Difference relative to add-on LABA
(95% CI)b
-£124 (-£135 to
-£114)
-£134 (-£142 to
-£125)
Trade-off: ICS step-up signiﬁcantly less
costly but marginally less effective
ICS step-up dominant: less costly and
more effective than separate
ICS ? LABA
Cost-effectiveness ratio (ICER) £51,499
Conﬁdence intervals determined using bootstrapping methods with 1000 random samples
CI conﬁdence interval, FDC ﬁxed-dose combination, ICER incremental cost-effectiveness ratio, ICS Inhaled corticosteroid,
LABA long-acting b2-agonist, OR Odds ratio
a Adjusted for: smoking status (current smoker/ex-smoker/nonsmoker/not speciﬁed), outpatient department attendance
for asthma/lower respiratory reasons, number of acute oral corticosteroid prescriptions, and oral thrush
b Conﬁdence intervals determined using bootstrapping methods with 1000 random samples
c Adjusted for baseline asthma-related healthcare costs
d Adjusted for number of acute oral corticosteroid prescriptions
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stepping up to a higher dose ICS would be less
costly but less effective (a trade-off); a point
estimate for the ICER, the monetary value of the
intangible benefit to patients or society beyond
the cost to achieve an additional controlled
patient using an FDC ICS/LABA inhaler, was
£51,449, reflecting the significantly higher costs
of FDC therapy and the non-significant
difference in effectiveness between treatments.
There was a 44% probability that stepping up to
a higher dose of extrafine-particle ICS would be
the preferred treatment strategy (less costly and
more effective). In our second comparison, ICS
step-up was the preferred treatment strategy
compared with adding LABA via separate
inhaler: there was a 100% probability that
stepping up to a higher dose of
extrafine-particle ICS would be less costly and
more effective. Of the two add-on LABA
alternatives (comparison 3, reported in the
supplementary material) prescribing an FDC
ICS/LABA inhaler was more costly but also
more effective (with 100% probability) than
prescribing a separate add-on LABA inhaler.
This study compared asthma-related direct
costs for different step-up strategies in a primary
care setting, which is where most patients with
asthma receive treatment in the UK, as in many
countries [39, 40]. There are only a few studies
that have examined real-life comparative costs
for asthma step-up therapy [41, 42]. For patients
with recent exacerbation or frequent SABA use
identified in a recent retrospective cohort study
conducted using a large US health insurance
dataset, Hagiwara and coworkers [41] found
that fluticasone/salmeterol combination was
more effective in decreasing exacerbations and
SABA use but more expensive than ICS dose
step-up with fluticasone. In a broad United
States (US) asthma population studied in
Fig. 2 Cost-effectiveness acceptability curve for an
increased dose of extraﬁne-particle ICS (ICS step-up)
relative to add-on LABA in a ﬁxed-dose combination
inhaler with ICS (ICS/LABA combination): Probability of
ICS step-up being cost-effective from the UK NHS
perspective, adjusted results. ICS Inhaled corticosteroid,
LABA Long-acting beta2-agonist, UK NHS United King-
dom National Health Service
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Table 3 Mean asthma-related drug prescriptions and unadjusted costs during the outcome year for patients receiving a
step-up in ICS dose versus add-on LABA by separate inhaler ? ICS (comparison 2)
Asthma-related resourcec Mean (SD) resource use Mean (SD) resource cost, £
ICS dose
step-up
(N5 3232)
Separate
ICS1 LABA
(N5 6464)
P valuea ICS dose
step-up
(N5 3232)
Separate
ICS1 LABA
(N5 6464)
P valuea
ICS inhalers 5.7 (4.1) 4.5 (4.1) \0.001 91 (69) 43 (50) \0.001
Fixed-dose combination ICS/
LABA inhalers
0.9 (3.2) 1.6 (4.5) \0.001 34 (134) 57 (168) \0.001
Long-acting b2-agonist inhalers 0.8 (21.8) 5.8 (24.7) \0.001 11 (52) 155 (150) \0.001
Short-acting b2-agonist inhalers 7.1 (8.0) 6.5 (7.7) \0.001 27 (58) 25 (51) 0.072
Leukotriene receptor antagonist
prescriptions
0.2 (1.0) 0.2 (1.2) 0.26 6 (42) 6 (40) 0.85
Antibiotic prescriptions 1.0 (1.7) 1.0 (1.9) 0.54 3 (11) 4 (15) 0.33
Oral corticosteroid prescriptions 0.4 (1.0) 0.4 (1.1) \0.001 1 (6) 2 (6) \0.001
Total mean medication costs – – – 174 (182) 292 (242) \0.001
Total mean medication costs,
excluding ICS
– – – 49 (92) 192 (173) \0.001
Primary care asthma
consultations
0.9 (1.3) 1.1 (1.4) \0.001 33 (48) 41 (52) \0.001
Total asthma-related
hospitalizations
0.0 (0.3) 0.1 (0.3) 0.050 8 (62) 13 (93) 0.006
Asthma-related inpatient 0.0 (0.1) 0.0 (0.1) 0.011 3 (49) 7 (80) 0.011
Asthma-related outpatient 0.0 (0.2) 0.0 (0.3) 0.16 4 (32) 5 (36) 0.16
Asthma-related emergency
department visit
0.0 (0.1) 0.0 (0.1) 0.94 1 (13) 1 (13) 0.94
Total asthma-related primary
and secondary care, including
ICS costs
– – – 215 (224) 345 (283) \0.001
Total asthma-related primary
and secondary care, excluding
ICS costs
– – – 90 (136) 246 (209) \0.001
Mean values are reported, despite substantially skewed distributions, because mean values can be multiplied by a target
population to estimate total costs and thus are of most interest for policy makers and providers
ICS inhaled corticosteroid, LABA long-acting b2-agonist, SD standard deviation
a Conditional logistic regression
b Asthma-related includes all database events coded for asthma and lower respiratory tract infection
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2002–2004, direct medical costs and
asthma-related healthcare resource utilization
were lower with ICS monotherapy as compared
with FDC ICS/LABA therapy (cost-effectiveness
was not reported) [42]. Other published
cost-effectiveness analyses based on short-term
RCT results report that FDC ICS/LABA therapy,
while more expensive, usually meets
benchmarks for cost-effectiveness [12–15].
Administering LABA by separate inhaler was
not a cost-effective alternative in this study as
compared with either ICS step-up or an FDC
ICS/LABA inhaler. Similar findings were
reported in prior RCTs [13]. In addition,
administering LABA by separate inhaler is
discouraged by asthma guidelines because
LABA monotherapy (without ICS) has been
associated with serious adverse asthma-related
outcomes, including deaths, seen in early trials
[8, 43]. Instead, an FDC ICS/LABA inhaler is
recommended to ensure that patients take
concomitant ICS.
A strength of this study is the large patient
population, with over 38,000 patients studied,
and the minimal exclusion criteria designed to
capture data for a broad general population
treated for asthma in primary care. Treatment
cohorts were matched according to several
criteria reflecting baseline asthma severity and
control. Effectiveness measures were adjusted
for residual confounding. Nonetheless, we
cannot exclude the possibility of unrecognized
confounders, including measures that were not
available for all patients, such as smoking status
and socioeconomic status, or that were not
present in the database, such as pack-years of
smoking. We were limited to the available
database information in developing our
asthma control measure; however, it would
have been of interest to also include
patient-reported outcomes (including actual
SABA use rather than inhalers prescribed) in
our definition of asthma control, as 58–65% of
each cohort were evaluated as controlled at
baseline according to our measure.
Nevertheless, all patients were prescribed a
step-up in therapy at the index date, which
suggests that they or their physician did not
consider their asthma to be well-controlled.
We had no way to measure patient
satisfaction with therapy; however, we inferred
from the treatment change data in the
companion effectiveness study that there were
no major differences in patient satisfaction
between ICS step-up and FDC ICS/LABA
step-up as the same proportions of patients in
the two cohorts changed therapy during the
outcome year [20]. Nevertheless, the issue of
patient satisfaction with step-up therapy would
be an important outcome to explore in a
pragmatic trial. Patient satisfaction and patient
preferences are potentially important influences
on patient adherence to therapy and hence
must be factored into clinical prescribing
decisions [3, 8]. In addition, ICS doses should
be tailored to the level of symptom control,
lung function, and exacerbations, all relating to
the degree of airways inflammation.
Double counting may have occurred in this
analysis because the numerator included the
difference in costs of asthma-related resource
utilization and the asthma control effectiveness
measure was a function of asthma-related
events. Therefore, the cost estimates in the
ICERs are interpreted as the willingness-to-pay
over and above the cost to achieve an additional
controlled patient. In other words, ICERs in this
case represent the monetary value of the
intangible benefit to patients or society
beyond the cost to achieve an additional
controlled patient over the outcome period
[44].
The ICER of £51,000 for prescribing FDC ICS/
LABA therapy instead of ICS dose step-up was
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calculated using a composite database measure
of risk-domain asthma control as the
effectiveness measure. The more common
calculation of ICER per additional
quality-adjusted life-year (QALY), as used by
the UK National Institute for Health and Care
Excellence (NICE), was not possible from the
available data. The cost-effectiveness threshold
used by NICE is £20,000 to £30,000 for cost per
QALY [45]. Because of our approach in using an
intermediate effectiveness measure instead of a
composite measure such as QALYs, we cannot
make comparisons to results from cost-utility
analyses for unrelated interventions or
treatments. To increase comparability with
unrelated interventions, future pragmatic trials
should address treatment preferences to
calculate both within-trial cost-per-QALY
ratios and projected lifetime cost-per-QALY
ratios using assumptions around
asthma-specific mortality.
In addition, our study findings apply
primarily to the UK healthcare system, and
further investigations are needed from other
perspectives, using different effectiveness
measures, and in the setting of other
healthcare systems, as costs are highly variable
among countries. Moreover, prescribing
preferences can vary according to location.
Assessment of indirect costs is needed as well.
We chose to investigate extrafine-particle
beclomethasone, with aerosol particle MMAD
of 1.1 lm, for the ICS step-up therapy because of
its good distribution to the small airways, often
a site of persistent inflammation in patients
with poorly controlled asthma [18, 46–48]. In a
prior, similarly designed cost-effectiveness
study of patients initiating ICS therapy for
asthma, we found that initiating with an
extrafine ICS as compared with standard
fine-particle ICS (MMAD of 2.4–3.2 lm,
depending on formulation) had C84%
probability of being the preferred treatment,
i.e., less costly and more effective, in both the
UK and the USA [49]. Further observational
studies are needed to compare the
cost-effectiveness of step-up regimens with
other extrafine-particle ICS, such as ciclesonide
(MMAD of 1.0 lm), and the standard
fine-particle ICS, such as fluticasone (MMAD,
2.4–5.4 lm) and budesonide
(MMAD,*4.0 lm).
CONCLUSIONS
We found that, among available step-up
therapy alternatives for adults with persistent
asthma on ICS monotherapy cared for in UK
clinical practice, adding a LABA via separate
inhaler is the least cost-effective option.
Increasing extrafine-particle ICS dose is
significantly less costly from the payer
perspective and marginally (non-significantly)
less effective than FDC ICS/LABA therapy
containing standard fine-particle ICS. From the
UK NHS payer perspective, the cost to achieve
an additional controlled patient using an FDC
ICS/LABA combination rather than ICS dose
step-up using extrafine particles is very high
(£51,449). In countries with strong economic
constraints, this may lead to questioning the
recommendation of FDC ICS/LABA as first
choice when treatment step-up is required,
especially when considering that
extrafine-particle ICS dose step-up has a 44%
probability of being the cost-effective option
relative to FDC ICS/LABA. These findings
warrant further investigation in other
healthcare systems and with a range of ICS in
pragmatic trials and observational studies.
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